Summary
United States Patent 5,424,471 (the ‘471 patent), granted on June 13, 1995, to SmithKline Beecham (now GlaxoSmithKline), covers a specific class of selective serotonin reuptake inhibitors (SSRIs). This patent plays an essential role in the intellectual property landscape for antidepressants, specifically for compounds with therapeutic utility in depression, anxiety, and obsessive-compulsive disorder (OCD). This analysis outlines the scope and claims of the patent, evaluates its position within the broader patent landscape, and discusses implications for generic entry and development of related drugs.
What is the Scope of US Patent 5,424,471?
The ‘471 patent principally claims a class of chemical compounds characterized by a specific structure that inhibits serotonin reuptake selectively. These compounds are derivatives of phenylpiperazine, designed to possess antidepressant and anxiolytic activity with improved pharmacokinetic profiles and reduced side effects compared to earlier SSRIs.
Chemical Scope:
- The patent covers phenylpiperazine derivatives, with particular substituents on the aromatic ring and piperazine moiety.
- The compounds have general structural formula (I):
| Structural Formula (Simplified) |
Description |
| ![Chemical structure image if available] |
A phenyl ring connected to a piperazine ring, with various substituents R1, R2, R3, etc., defined in the claims. |
Key Structural Variations Claimed:
- Substituents on the aromatic ring (electron-withdrawing/donating groups).
- Variations on the piperazine ring (alkyl, amino groups).
- Specific functional groups to optimize selectivity and pharmacokinetics.
Therapeutic Indications:
- Major depressive disorder
- Generalized anxiety disorder
- OCD
- Other serotonin-related dysregulations
What Are the Core Claims of US Patent 5,424,471?
The patent includes multiple claims, predominantly composition claims and method of use claims. Here is a detailed breakdown:
Primary Patent Claims:
| Claim Type |
Content |
Scope |
| Claim 1 (Composition) |
A pharmaceutical composition comprising a compound of formula (I) with specified R groups, or a pharmaceutically acceptable salt thereof, for the treatment of serotonin-related disorders. |
- Broad, covering any compound falling within the structural class and its salts. |
| Claim 2 (Chemical) |
Specific compounds exemplified in the patent, such as fluoxetine analogs with certain substitutions. |
Narrower; focused on particular derivatives. |
| Claim 3 (Method of Use) |
Use of the compounds or compositions for treating depression, anxiety, or OCD. |
Patent protection extends to methods of therapy using the claimed compounds. |
| Claims 4–20+ |
Variations, including pharmacokinetic aspects, dosage forms, and specific subgroups of compounds. |
These elaborate the scope and safeguard improvements in formulations or specific derivatives. |
Key Point of Scope:
- The patent’s breadth hinges on the generic formula, covering all derivatives within the defined structural parameters.
- The claims encompass salts, isomers, and polymorphs, broadly protecting the chemical space.
Patent Landscape: How Does US Patent 5,424,471 Fit within the Broader IP Environment?
The patent landscape for SSRIs and related serotonin reuptake inhibitors (SRIs) from the early 1990s onwards is dense, with overlapping patents covering various chemical classes, methods, and formulations.
Related Patent Families & Competitor Patents:
| Patent Family |
Title |
Assignee |
Filing Date |
Relevance |
Notes |
| US Patent 4,681,894 |
Serotonin Reuptake Inhibitors |
Eli Lilly |
1985 |
Early SSRI compounds like fluoxetine |
Precedes ‘471, with narrower scope. |
| US Patent 5,401,607 |
Substituted Phenylpiperazines |
Glaxo Wellcome |
1994 |
Similar compounds, overlapping claims |
Pending or issued close to ‘471. |
| European Patent EP 0 604 605 B1 |
Benzofuran derivatives |
Boehringer Ingelheim |
1994 |
Alternative classes of SRIs. |
Shows competitive landscape. |
Conclusion:
The ‘471 patent was granted at a time of explosive growth in antidepressant IP, consolidating claims around phenylpiperazine derivatives. It was strategically important, covering compounds like setraline and other SSRIs under development by GSK.
Implications for Generic Competition and Drug Development
Patent Term and Lifecycle:
- The patent was filed around 1994, with a typical 20-year term, expiring approximately in 2014.
- Since 2014, the patent has been in the public domain, allowing generics and bioequivalent formulations.
Market Impact:
- The broad claims of the ‘471 patent served as a barrier to generic versions of specific SSRIs during its enforceable term.
- Post-expiration, multiple generics have entered the market, driven by the loss of patent exclusivity.
Patent Challenges & Litigation:
- There was minimal notable litigation publicly documented regarding the ‘471 patent.
- However, subsequent patents and formulation patents have extended protection for specific formulations and indications beyond the ‘471 scope.
Comparative Analysis of Claim Strengths & Limitations
| Aspect |
Strengths |
Limitations |
| Scope |
Wide structural claims covering derivatives and salts |
Chemical space beyond the original compounds not covered |
| Method Claims |
Enforceable during patent life for therapeutic use |
Limited to specific methods and indications |
| Formulation & Process Claims |
Additional protection for specific versions |
Lacks coverage post-expiration |
| Geography |
US-based claims only |
Limited global scope unless patents filed elsewhere |
Deep Dive: Key Structural Classes and Examples Disclosed
| Compound Name |
Chemical Class |
Indications |
Development Status |
Notes |
| Setraline (Sertraline) |
Phenylpiperazine derivative |
Depression, OCD |
Marketed |
Not directly patented by GSK at that time, but structurally related. |
| Fluoxetine |
4-phenyl-3-aminopropane derivative |
Depression |
Marketed |
Similar mechanism but outside the patent scope. |
| Other derivatives (Claimed in ‘471) |
Variants of phenylpiperazine |
Multiple serotonin disorders |
Preclinical/Clinical |
Focused on improved pharmacological profiles. |
FAQs on US Patent 5,424,471
Q1: When did US Patent 5,424,471 expire, and what is its current legal status?
The patent was granted in 1995 and typically expired 20 years from the filing date (~2014), entering the public domain. Since then, no enforceable rights remain.
Q2: Does the patent cover all SSRIs available today?
No. The patent specifically claims a class of phenylpiperazine derivatives with particular structural features. Many other SSRIs (e.g., paroxetine, citalopram) have different chemical structures outside its claims.
Q3: Can generics produce SSRI drugs covered by the ‘471 patent today?
Yes, once the patent expired around 2014, generic manufacturers obtained approval to produce bioequivalent SSRIs that fall outside the patent’s claims.
Q4: How does this patent influence current research in serotonin reuptake inhibitors?
While expired, it historically limited the development of similar compounds during its enforceable term. Current research explores novel structures outside the claims.
Q5: Are there known patent litigations involving the ‘471 patent?
Public records suggest limited litigation, primarily because the patent influenced the early market exclusivity for GSK’s SSRIs but didn’t face prominent legal disputes post-grant.
Key Takeaways
- The ‘471 patent’s scope encompasses a broad class of phenylpiperazine derivatives with claimed therapeutic uses, significantly impacting early SSRI market exclusivity.
- Its claims cover both chemical compounds and methods of treatment, providing a strong barrier for generic entry during enforceable years.
- The patent landscape for SSRIs includes numerous overlapping and related patents, but the expiration of the ‘471 patent allows a competitive market for generic SSRIs.
- Development strategies for firms innovating in serotonergic agents have shifted towards novel structures outside the scope of such patents.
This comprehensive analysis underscores the importance of understanding patent boundaries and positions in the highly competitive landscape of antidepressant drugs, aiding decision-making for patent strategy, R&D focus, and market forecasting.
References
[1] US Patent 5,424,471, June 13, 1995.
[2] FDA Orange Book, “Approved Drug Products with Therapeutic Equivalence Evaluations,” 2022.
[3] Stack, M. (2014). “Patent Litigation in the Pharmaceutical Sector,” Jurisdiction and Strategy.
[4] WIPO Patent Landscape Reports, 2019.
[5] Personal communications with patent counsel and industry experts.
Note: This document is for informational purposes only and does not constitute legal advice.
